CUMYL-CBMICA

CUMYL-CBMICA
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name 1-(cyclobutylmethyl)-N-(2-phenylpropan-2-yl)indole-3-carboxamide;
CAS Number	2571070-88-5 ;
PubChem CID	155884426;
ChemSpider	84400460;
UNII	GPD3YVJ5RT;
CompTox Dashboard (EPA)	DTXSID001336648 ;
Chemical and physical data
Formula	C23H26N2O
Molar mass	346.474 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(NC(=O)c3cn(CC1CCC1)c2ccccc23)c4ccccc4;
	InChI InChI=1S/C23H26N2O/c1-23(2,18-11-4-3-5-12-18)24-22(26)20-16-25(15-17-9-8-10-17)21-14-7-6-13-19(20)21/h3-7,11-14,16-17H,8-10,15H2,1-2H3,(H,24,26); Key:INXXQNIOWMOYEJ-UHFFFAOYSA-N;

CUMYL-CBMICA (SGT-280) is an indole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug,^[1]^[2] first being identified in Germany in August 2019. Since the structure fell outside the German drug analogue law provisions at the time, an amendment was made to the law to expand the relevant definition, which came into effect in April 2020.^[3] It has been shown to act as a CB₁ receptor agonist with an EC₅₀ of 62.9nM.^[4]